文獻(xiàn)： 1、" Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. " Pharmacotherapy 2007;27:290–8. Page RL, Schwiesow J, Hilts A. 2、Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39:310–24. Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. 3、Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. 4、J Med Chem, 51: 4632～4640. Org. Process Res. Dev. 2019, 23, 9, 2057-2068 Pharmazie 73(9):494-497 · September 2018 5、中國(guó)醫(yī)藥工業(yè)雜志 2012， 43（8）， 644-646 6、精細(xì)化工中間體2013，43（2），46-48 7、精細(xì)化工中間體2011，41（4），46-48 8、中國(guó)現(xiàn)代應(yīng)用藥學(xué)2011，28（1），58-59 9、Chemical biology&Drug Design 2014, 83(3), 306-316 10、Letters in organic chemistry 2012, 9(4), 276-279 11、Medicines Evidence Commentary : Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders Source: National Institute for Health and Care Excellence - NICE - 21 January 2014 - Publisher: National Institute for Health and Care Excellence (NICE) 12、double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children 13、J. Med. Chem. 2018, 61, 5304?5322. 14、Chem. Biol. Drug Des. 2014, 83, 306?316. 15、J. Pharm. Biomed. Anal. 2009, 50, 144?150. 16、Int. J. Pharm. Sci. 2016, 8, 97?102. 17、J. Pharm. Biomed. Anal. 2010, 52, 493?507. 18、Org. Process Res. Dev. 2013, 17, 1036?1041. 19、Beilstein J. Org. Chem. 2011, 7, 442? 495. 20、Bioorg. Med. Chem. Lett. 2014, 24, 1108?1110. 21、New Activated PEG Derivatives for Affinity Partitioning 22、Population incidence and mortality of sepsis in an urban African setting 2013-2016 23、Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in   [更多]

1、Arzneimittelforschung. 1985;35(7A):1203-8. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. 2、Arzneimittelforschung. 1985;35(7A):1149-54. K Kawamura, K Watanabe, Y Kimura. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation 3、Gel formation of cefpodoxime proxetil 4、Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis. GK Webster, RG Bell - Journal of AOAC International, 1999 - europepmc.org 5、Rydell N, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.Ⅵ. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of the arthritis in track horses. Acta Vet Scand, 1970,11:139~146 6、Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol, 1974, 22:731~736 7、Weiss C, Balazs EA, St Onge R, et al. Clinical studies of the intra-articular injection of Healon in the treatment of osteoarthritis of human knee. Semin Arhtritis Rheum, 1980, 11(Suppl 1):143~144 8、Punzi L, Schiavon F, Ramonda R, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and non-inflammatory knee diffusions. Curr Ther Res, 1988, 43:643~647 9、Nolan JP, reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice, 2007 10、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

USP39的Calcium Gluconate和Calcium Gluconate Injection標(biāo)準(zhǔn)，要求翻譯為中文   [更多]

MONOGRAPHS: Levofloxacin《USP43-NF38》的藥典標(biāo)準(zhǔn)一份 USP MONOGRAPHS: Levofloxacin Tablets《USP43-NF38》的藥典標(biāo)準(zhǔn)一份 Levofloxacin Tablets《USP–NF 2021(Issue 2)》的藥典標(biāo)準(zhǔn)一份 Levofloxacin《USP–NF 2021(Issue 2)》的藥典標(biāo)準(zhǔn)一份 左氧氟沙星、片藥品注冊(cè)標(biāo)準(zhǔn) Levofloxacin Fine Granules《JP17(英)》的藥典標(biāo)準(zhǔn)一份   [更多]

倍他環(huán)糊精 最新的歐洲藥典 至少是EP9.2   [更多]

求購(gòu)二巰基丙磺酸鈉（巰丙磺鈉）注射液標(biāo)準(zhǔn)一份   [更多]

需要分類(lèi)的數(shù)據(jù)有24300條，數(shù)據(jù)里面包含了藥品、保健品及醫(yī)療器械，現(xiàn)在請(qǐng)人對(duì)數(shù)據(jù)進(jìn)行分類(lèi)，我方會(huì)提供分類(lèi)代碼表，只需填寫(xiě)分類(lèi)代碼到相應(yīng)地方即可   [更多]

標(biāo)題：請(qǐng)人查關(guān)于Faropenem Sodium Hydrate《JP17(英)》及Faropenem Sodium Tablets《JP17(英)》的藥典標(biāo)準(zhǔn) 需求名稱(chēng)：Faropenem Sodium Hydrate《JP17(英)》及Faropenem Sodium Tablets《JP17(英)》的藥典標(biāo)準(zhǔn) 價(jià)格預(yù)算：50元 需求時(shí)間：請(qǐng)?jiān)?020年11月28號(hào)之前提交 交稿方式：請(qǐng)將文獻(xiàn)直接打包在藥智網(wǎng)交稿就可以了   [更多]

具體要求： 求購(gòu)“Antimony potassium tartrate.”《 EP9.4 》的歐洲藥典標(biāo)準(zhǔn)一份.   [更多]

1、懸賞的藥品注冊(cè)信息為2016年1月1日之后不批準(zhǔn)、退審的藥品注冊(cè)信息和補(bǔ)充藥品注冊(cè)信息 2、必須提供完整注冊(cè)信息,以附件形式提交 （以單個(gè)批件形式提交）3、核實(shí)后如果正確,每個(gè)藥品注冊(cè)信息獎(jiǎng)勵(lì)100元 4、投稿時(shí)請(qǐng)隱藏提交 5、請(qǐng)勿在百度上直接搜索 6、需是未收集的數(shù)據(jù)   [更多]